These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma. Schneeberger VE; Ren Y; Luetteke N; Huang Q; Chen L; Lawrence HR; Lawrence NJ; Haura EB; Koomen JM; Coppola D; Wu J Oncotarget; 2015 Mar; 6(8):6191-202. PubMed ID: 25730908 [TBL] [Abstract][Full Text] [Related]
3. The gain-of-function mutation E76K in SHP2 promotes CAC tumorigenesis and induces EMT via the Wnt/β-catenin signaling pathway. Zhang Q; Li Y; Zhao R; Wang X; Fan C; Xu Y; Liu Y; Li J; Wang S Mol Carcinog; 2018 May; 57(5):619-628. PubMed ID: 29323748 [TBL] [Abstract][Full Text] [Related]
4. Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants. Fan YX; Wong L; Marino MP; Ou W; Shen Y; Wu WJ; Wong KK; Reiser J; Johnson GR J Biol Chem; 2013 Jun; 288(23):16895-16904. PubMed ID: 23612964 [TBL] [Abstract][Full Text] [Related]
5. Induction of a tumor-associated activating mutation in protein tyrosine phosphatase Ptpn11 (Shp2) enhances mitochondrial metabolism, leading to oxidative stress and senescence. Zheng H; Li S; Hsu P; Qu CK J Biol Chem; 2013 Sep; 288(36):25727-25738. PubMed ID: 23884424 [TBL] [Abstract][Full Text] [Related]
6. Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations. Furcht CM; Muñoz Rojas AR; Nihalani D; Lazzara MJ Oncogene; 2013 May; 32(18):2346-55, 2355.e1-10. PubMed ID: 22777356 [TBL] [Abstract][Full Text] [Related]
7. Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner. Zheng H; Yu WM; Waclaw RR; Kontaridis MI; Neel BG; Qu CK Sci Signal; 2018 Mar; 11(522):. PubMed ID: 29559584 [TBL] [Abstract][Full Text] [Related]
8. Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition. Chen L; Chen W; Mysliwski M; Serio J; Ropa J; Abulwerdi FA; Chan RJ; Patel JP; Tallman MS; Paietta E; Melnick A; Levine RL; Abdel-Wahab O; Nikolovska-Coleska Z; Muntean AG Leukemia; 2015 Jun; 29(6):1290-300. PubMed ID: 25650089 [TBL] [Abstract][Full Text] [Related]
9. Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells. Xu D; Liu X; Yu WM; Meyerson HJ; Guo C; Gerson SL; Qu CK J Exp Med; 2011 Sep; 208(10):1977-88. PubMed ID: 21930766 [TBL] [Abstract][Full Text] [Related]
10. Activated Notch1 induces lung adenomas in mice and cooperates with Myc in the generation of lung adenocarcinoma. Allen TD; Rodriguez EM; Jones KD; Bishop JM Cancer Res; 2011 Sep; 71(18):6010-8. PubMed ID: 21803744 [TBL] [Abstract][Full Text] [Related]
11. A tyrosine phosphatase SHP2 gain-of-function mutation enhances malignancy of breast carcinoma. Hu Z; Wang X; Fang H; Liu Y; Chen D; Zhang Q; Liu X; Wei D; Qu C; Wang S Oncotarget; 2016 Feb; 7(5):5664-76. PubMed ID: 26673822 [TBL] [Abstract][Full Text] [Related]
12. Genetic disruption of the scaffolding protein, Kinase Suppressor of Ras 1 (KSR1), differentially regulates GM-CSF-stimulated hyperproliferation in hematopoietic progenitors expressing activating PTPN11 mutants D61Y and E76K. Yang Z; Chen M; Sitarski SA; Saadatzadeh T; Yin F; Yu M; Yang FC; Chan RJ Leuk Res; 2011 Jul; 35(7):961-4. PubMed ID: 21555152 [TBL] [Abstract][Full Text] [Related]
13. Src-homology 2 domain-containing tyrosine phosphatase 2 promotes oral cancer invasion and metastasis. Wang HC; Chiang WF; Huang HH; Shen YY; Chiang HC BMC Cancer; 2014 Jun; 14():442. PubMed ID: 24931737 [TBL] [Abstract][Full Text] [Related]
14. Conditional expression of the mutant Ki-rasG12C allele results in formation of benign lung adenomas: development of a novel mouse lung tumor model. Floyd HS; Farnsworth CL; Kock ND; Mizesko MC; Little JL; Dance ST; Everitt J; Tichelaar J; Whitsett JA; Miller MS Carcinogenesis; 2005 Dec; 26(12):2196-206. PubMed ID: 16051643 [TBL] [Abstract][Full Text] [Related]
15. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. Mainardi S; Mulero-Sánchez A; Prahallad A; Germano G; Bosma A; Krimpenfort P; Lieftink C; Steinberg JD; de Wit N; Gonçalves-Ribeiro S; Nadal E; Bardelli A; Villanueva A; Bernards R Nat Med; 2018 Jul; 24(7):961-967. PubMed ID: 29808006 [TBL] [Abstract][Full Text] [Related]
16. Gain-Of-Function E76K-Mutant SHP2 Promotes Cell Proliferation, Metastasis, And Tumor Growth In Glioblastoma Through Activation Of The ERK/CREB Pathway. Yang F; Xu M; Wang S; Song L; Yu D; Li Y; Cao R; Xiong Z; Chen Z; Zhang Q; Zhao B; Wang S Onco Targets Ther; 2019; 12():9435-9447. PubMed ID: 31807022 [TBL] [Abstract][Full Text] [Related]
17. Identification of tumorigenic cells in Kras(G12D)-induced lung adenocarcinoma. Cho HC; Lai CY; Shao LE; Yu J Cancer Res; 2011 Dec; 71(23):7250-8. PubMed ID: 22088965 [TBL] [Abstract][Full Text] [Related]
18. Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase. Ruess DA; Heynen GJ; Ciecielski KJ; Ai J; Berninger A; Kabacaoglu D; Görgülü K; Dantes Z; Wörmann SM; Diakopoulos KN; Karpathaki AF; Kowalska M; Kaya-Aksoy E; Song L; van der Laan EAZ; López-Alberca MP; Nazaré M; Reichert M; Saur D; Erkan MM; Hopt UT; Sainz B; Birchmeier W; Schmid RM; Lesina M; Algül H Nat Med; 2018 Jul; 24(7):954-960. PubMed ID: 29808009 [TBL] [Abstract][Full Text] [Related]
19. LEOPARD-type SHP2 mutant Gln510Glu attenuates cardiomyocyte differentiation and promotes cardiac hypertrophy via dysregulation of Akt/GSK-3β/β-catenin signaling. Ishida H; Kogaki S; Narita J; Ichimori H; Nawa N; Okada Y; Takahashi K; Ozono K Am J Physiol Heart Circ Physiol; 2011 Oct; 301(4):H1531-9. PubMed ID: 21803945 [TBL] [Abstract][Full Text] [Related]
20. Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature. De Rocca Serra-Nédélec A; Edouard T; Tréguer K; Tajan M; Araki T; Dance M; Mus M; Montagner A; Tauber M; Salles JP; Valet P; Neel BG; Raynal P; Yart A Proc Natl Acad Sci U S A; 2012 Mar; 109(11):4257-62. PubMed ID: 22371576 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]